INTRODUCTION:

SARS-CoV-2 outbreak and its rapid worldwide spread, WHO declared it a global health emergency on January 31, 2020. WHO classified this as coronavirus illness 2019 in February 2020^1-5. (COVID-19). According to WHO data on January 6, 2022, about 296.4 million COVID-19 cases have been registered worldwide, with 5.46 million deaths.

This infectious disease has widespread symptoms ranging from asymptomatic patients to standard flu symptoms such as cough, sore throat, fever, headache, body discomfort, dyspnoea, and acute respiratory distress syndrome. Some individuals also complained of gastrointestinal issues, such as stomach pain and diarrhoea. COVID-19 patients may present with a severe viral infection, a reduced immunological system, and eventually develop substantial cytokine storms, lung fibrosis lesion, and multiorgan failure, which can lead to death⁶.

COVID-19 has been treated using a variety of approaches. These include RNA-dependent RNA polymerase inhibitors such as Remdesivir, Ribavirin, and Favipiravir; protease inhibitors such as Lopinavir/ritonavir; endosomal acidification inhibitors (azithromycin, Chloroquine, and hydroxychloroquine); monoclonal or polyclonal antibodies; adjunctive treatments (Tocilizumab) for decreasing IL-6 in cytokine storm. COVID-19 symptoms are non-specific and range from asymptomatic to severe pneumonia, which includes fever, coughing, shortness of breath, and death. COVID-19 symptoms include headache, fatigue, anosmia, sore throat, increased sputum production, rhinorrhea, anorexia, dyspnea, pleurisy, skin sensitivity, hemoptysis, myalgias, and diarrhoea. An infected person may develop pathological signs such as moderate respiratory problems with fever after an average incubation time of 5-6 days following infection. Many case reports revealed that the mortality rate increases with age, with people over 80 years old having the highest mortality rate and people over 60 years old having other disorders such as diabetes, hypertension, chronic respiratory disease, cardiovascular disease, and cancer having the lowest mortality rate⁷.

The purpose of this part of the Guidelines is to provide general information to health care providers who are caring for adults with COVID-19 who have not been hospitalized. Pharmacological Management of Nonhospitalized Adults with COVID-19 includes the pharmacologic management recommendations provided by the COVID-19 Treatment Guidelines Panel. The Panel is cognizant that there may be occasions during the COVID-19 pandemic when it is difficult to differentiate between outpatient and inpatient care. In the case that there is a shortage of hospital beds, medical teams, or resources, patients with COVID-19 may receive care outside of the conventional ambulatory care or hospital settings. Furthermore, during a patient's hospitalization for a condition other than COVID-19, nonspecific SARS-CoV-2 infection or a mild sickness may be detected. When deciding whether to follow the recommendations in this paper, healthcare providers should use their professional judgement^3-4.

This section focuses on the assessment and administration of:

· COVID-19-positive adults receiving ambulatory care

· Adults who have COVID-19 after being discharged from the ER (ED)

· Adults discharged from a hospital with COVID-19

Each of these settings may use some or all the following for outpatient evaluation and management, including telemedicine, remote monitoring, in-person visits, and home visits by nurses or other medical professionals.

Racial and ethnic minorities have greater incidence of COVID-19, hospitalization, and death, according to data from the United States. 1-5 Inequitable COVID-19 therapy delivery by race, ethnicity, and socioeconomic status. The underlying factors causing these observed discrepancies may be obstacles to telehealth visits, problems with transportation, insufficient insurance coverage, a shortage of primary care doctors, and reluctance to seek treatment. Providers need to be aware of the issue and offer patient-centred care to eliminate COVID-19 treatment discrepancies. No patient group should be denied access to care because of their colour, ethnicity, or other status as a minority^3-5.

METHODS:

Materials:

Nearly 80% of COVID-19 patients who are unvaccinated have a mild illness that doesn't need medical attention or hospitalization, and this percentage is probably higher among individuals who have received the vaccine. Most COVID-19 patients can be treated in an outpatient setting or at home if viral pneumonia and hypoxemia are not present. Patients with mild COVID-19 (viral pneumonia without hypoxemia) or severe COVID-19 (dyspnea, hypoxemia, or lung infiltrates greater than 50%) require in-person evaluation and close monitoring since pulmonary illness can advance quickly and necessitate hospitalization³.

COVID-19-positive adults receiving ambulatory care:

Clinicians should offer supportive care, follow CDC recommendations for lowering the risk of SARS-CoV-2 transmission, and counsel patients on when to seek an in-person examination when managing outpatients with COVID-19. Supportive care entails controlling symptoms (as detailed below), making sure patients are getting the right diet, and being aware of the dangers of social isolation, especially for older persons. Patients who are at a high risk of developing severe COVID-19 should be identified by healthcare professionals. These individuals could benefit from antiviral medication, such as anti-SARS-CoV-2 monoclonal antibody therapy (mAb)^3-10.

Hospitalization and death risk are increased in older individuals and those with chronic illnesses. However, even in the absence of risk factors, SARS-CoV-2 infection can result in serious illness and death in people of any age. Factors like cognitive impairment, frailty, the risk of falls, and polypharmacy should be considered when caring for older persons with COVID-19. Every situation should be considered individually when deciding whether to monitor a patient in an outpatient environment^3-5.

When it is practical, telehealth visits should be used to triage patients who have COVID-19 symptoms to identify whether they need in-person treatment and COVID-19-specific therapy. The use of patient self-assessment instruments may be part of outpatient management. Clinic staff should decide at the initial triage which patients are qualified for supportive care at home and which patients require an in-person review. When determining if an in-person evaluation is necessary, the patient's local emergency medical services, if they are called, may also be helpful. Health care professionals should at the very least employ telemedicine to closely monitor patients who have dyspnea, and in-person monitoring of these patients should be taken into consideration. Referrals to a health care provider for an in-person evaluation should be made for patients with persistent or progressive dyspnea, especially those who have an oxygen saturation measured by pulse oximetry (SpO2) 94% on room air at sea level or have symptoms that suggest high acuity. Clinicians should conduct assessments in the context of a patient's clinical condition and be mindful of the significant limitations of pulse oximeters when using SpO2 findings to evaluate patients. For more information, see Clinical Spectrum of SARS-CoV-2 Infection^1-9.

Depending on the location and institution, different therapeutic settings may be appropriate for an in-person evaluation based on different criteria. As new information and treatment alternatives are developed, it can potentially evolve over time. Older adults and those with medical illnesses linked to an elevated likelihood of progression to severe COVID-19 should have a low threshold for in-person evaluation. The initial triage team members should utilize their clinical judgment to decide if patients need to be transported by ambulance^3-10.

Adults who have COVID-19 after being discharged from the ER (ED):

SARS-CoV-2 infection patients may not show any symptoms or have signs that are like those of other acute viral or bacterial illnesses. People who exhibit COVID-19-compatible symptoms ought to get SARS-CoV-2 testing as a diagnostic measure. It's crucial to consider additional potential causes of symptoms, such as various respiratory virus infections, community-acquired pneumonia, congestive heart failure, exacerbations of asthma or chronic obstructive pulmonary disease, and streptococcal pharyngitis¹⁰.

Even though mild dyspnea is typical, it is possible for pulmonary involvement to begin or progress if dyspnea worsens and chest discomfort or tightness is severe. A median of 2.5 days passed following the onset of dyspnea in investigations of patients who experienced acute respiratory distress syndrome. Health care professionals should at the very least employ telemedicine to closely monitor patients who have dyspnea, and in-person monitoring of these patients should be taken into consideration¹⁷. Referrals to a healthcare provider for an in-person evaluation should be made for patients with persistent or progressive dyspnea, particularly those who have a SpO2 94% on room air at sea level or exhibit symptoms that point to high acuity (such as chest pain or tightness, dizziness, confusion, or other changes in mental status). SpO2 measures can be used to evaluate a patient's overall clinical status if they have access to a pulse oximeter at home. For optimal accuracy, patients should be instructed to use warm fingers rather than cold fingers while using pulse oximeters. If the reading consistently falls below 95% on room air at sea level, patients should contact their healthcare professionals. Particularly in patients with dark skin pigmentation, pulse oximetry may not reliably identify hypoxemia^10-13. The FDA has not approved all commercially available pulse oximeters in all cases (FDA). For clinical usage, SpO2 values acquired from non-FDA-cleared devices such as over-the-counter sports oximeters or mobile phone applications are insufficiently accurate. A device that has received FDA clearance or an arterial blood gas analysis should be used to confirm any abnormal findings from these devices. Importantly, the full clinical picture of a patient should only be considered when interpreting SpO2 measurements^13-18.

Patients who are at a high risk of disease development should be identified by healthcare professionals. These individuals might benefit from antiviral medication, such as anti-SARS-CoV-2 mAb therapy. The proper medical follow-up for these patients should be guaranteed by clinicians. The likelihood of a serious illness, the severity of the symptoms, and the patient's capacity to self-report deteriorating symptoms will all affect how frequently and how long the patient is followed up. A patient's access to a phone, computer, or tablet for telehealth, their ability to get to and from appointments, and their frequent access to food are all things that healthcare professionals should consider. The doctor should establish that the patient has a caregiver who is available to help with daily tasks if necessary^15-19.

Adults discharged from a hospital with COVID-19:

There are no set standards for admitting COVID-19 patients to hospitals; standards may change depending on the location and type of hospital. Usually, patients with severe illnesses are admitted to the hospital. Rarely, a patient with a severe illness might not be admitted because of a high infection rate and a lack of hospital resources. Furthermore, patients who could receive the right care at home but can't be managed properly in their typical residential setting are candidates for short-term housing in supervised facilities, such a COVID-19 alternative care facility. 26 Patients who are homeless or who live in multigenerational households, for instance, could find it difficult to separate themselves and should, where possible, be given access to resources like special housing units or hotel rooms.Since there aren't many residential care facilities specifically for COVID-19 patients, it's important to look for community-based options for isolation and self-care.Patients with mild to severe COVID-19 who are not receiving supplemental oxygen and who are at high risk of clinical progression are advised to get treatment with an antiviral medication or anti-SARS-CoV-2 mAb^20-23.

Most patients who leave a hospital setting should schedule a follow-up appointment with a healthcare professional soon after leaving. The clinical and social context will determine whether an in-person or telemedicine visit is best. Adult patients may occasionally be deemed stable enough to be released from the inpatient setting, even though they still need extra oxygen. In this situation, continuing some medications, such dexamethasone, may receive special consideration. These patients should, wherever practical, get close monitoring through oximetry, telehealth visits, visiting nurse services, or in-person clinic visits^24-26.

Adults Pregnant Care and COVID-19:

Using COVID-19, managing pregnant outpatients is like managing non-pregnant patients (see Special Considerations in Pregnancy). Clinicians should take precautions to lower the risk of SARS-CoV-2 transmission, provide advice on whether to seek an in-person examination, and provide supportive care and medications as needed²⁷. To reduce the danger of SARS-CoV-2 transmission to patients, caregivers, and staff, the American College of Obstetricians and Gynaecologists (ACOG) has produced guidelines on how to use telemedicine for prenatal care and how to modify standard prenatal care when appropriate²⁸.

The threshold for monitoring pregnant patients in a hospital setting may be lower than for non-pregnant patients since SpO2 in pregnant patients should be maintained at 95% or higher on room air at sea level. Fetal surveillance and management should be the same as those used for pregnant patients with medical illnesses; there are currently no changes to the recommendations for Fetal monitoring in the outpatient setting. However, a case-by-case discussion with an obstetrician is possible regarding these monitoring techniques. To aid in decision-making in this demographic, pregnant and lactating patients should be given the chance to take part in clinical studies of COVID-19 conducted as outpatients²⁹.

CONCLUSION:

The findings of this systematic review indicate that using COVID-19 management policy by CDC for non-hospitalized person. The effect rate, chest CT pictures, WBC count, absolute lymphocyte count, lymphocyte percentage, and C-Reactive protein level all improved^30-32. However, because of the scarcity of high-quality clinical trials and the significant degree of variability in the included research, a more definitive conclusion on the effects of herbal therapies on lowering body temperature and adverse effects could not be reached at this time. There are some differences in the therapeutic effects of different herbal therapies. Despite the fact that the COVID-19 pandemic is still ongoing, significant progress has been made in pathogen monitoring, identifying sources, fundamental etiology, and clinical therapy. All adults with mild to moderate COVID-19 who are not hospitalized should begin symptom management³³. Several antiviral therapy alternatives are available for individuals who are highly susceptible to the development of severe illness, lowering the risk of hospitalization or death. The guidelines for using these medications to treat COVID-19 are given in this section by the COVID-19 Treatment Guidelines Panel (the Panel). Preventing the progression of a serious illness, hospitalization, or death is the aim of therapeutic management for non-hospitalized patients³⁴. The choice of the appropriate course of treatment for a given patient is influenced by a number of factors. These considerations include the therapeutic effectiveness and accessibility of the recommended course of action, the practicality of giving parenteral drugs, the possibility of serious drug-drug interactions, the patient's pregnant status, and the passage of time^35-44.

CONFLICT OF INTEREST:

The authors have no conflicts of interest.

ACKNOWLEDGMENTS:

The authors would like to thank NCBI, PubMed and Web of Science for the free database services for their kind support during this study.

REFERENCES:

1. Anonymous, 2020a. Report of the WHO-China joint mission on coronavirus disease 2019 (COVID-19). https://www.who.int/publications/i/item/report-of-the-who-china-joint-mission-on-coronavirus-disease-2019-(covid-19). (Accessed on April 12, 2021).

2. Anonymous, 2020b. WHO, Africa CDC push for COVID-19 traditional medicine research in Africa. https://www.who.int/news-room/feature-stories/detail/who-africa-cdc-push-for-covid-19-traditional-medicine-research-in-africa. (Accessed on April 15, 2021).

3. Anonymous, 2021. WHO coronavirus disease (COVID-19) Dashboard (2021). https://covid19.who.int/. (Accessed on June 22, 2021)

4. Chanda, Debrabata, Jesus Prieto-Lloret, Arjun Singh, Hina Iqbal, Pankaj Yadav, Vladimir Snetkov, and Philip I Aaronson. Glabridin-Induced Vasorelaxation: Evidence for a Role of BKCa Channels and Cyclic GMP. Life Sciences. 2016; 165: 26–34. https://doi.org/10.1016/j.lfs.2016.09.018.

5. Gautam, Yashveer, Sonam Dwivedi, Ankita Srivastava, Hamidullah, Arjun Singh, D. Chanda, Jyotsna Singh, Smita Rai, Rituraj Konwar, and Arvind S. Negi. 2-(3′,4′-Dimethoxybenzylidene) Tetralone Induces Anti-Breast Cancer Activity through Microtubule Stabilization and Activation of Reactive Oxygen Species. RSC Advances. 2016; 6(40): 33369–79. https://doi.org/10.1039/C6RA02663J.

6. Hamid, A.A., Mohammad Hasanain, Arjun Singh, Balakishan Bhukya, Omprakash, Prema G. Vasudev, Jayanta Sarkar, et al. “Synthesis of Novel Anticancer Agents through Opening of Spiroacetal Ring of Diosgenin. 2014; 87: 108–18. https://doi.org/10.1016/j.steroids.2014.05.025.

7. Hamid, A.A., Tanu Kaushal, Raghib Ashraf, Arjun Singh, Amit Chand Gupta, Om Prakash, Jayanta Sarkar, et al. (22β,25R)-3β-Hydroxy-Spirost-5-En-7-Iminoxy-Heptanoic Acid Exhibits Anti-Prostate Cancer Activity through Caspase Pathway. Steroids. 2017; 119: 43–52. https://doi.org/10.1016/j.steroids.2017.01.001.

8. Jain, Shilpi, Arjun Singh, Puja Khare, D. Chanda, Disha Mishra, Karuna Shanker, and Tanmoy Karak. Toxicity Assessment of Bacopa Monnieri L. Grown in Biochar Amended Extremely Acidic Coal Mine Spoils. Ecological Engineering. 2017; 108: 211–19. https://doi.org/10.1016/j.ecoleng.2017.08.039.

9. Khwaja, Sadiya, Kaneez Fatima, Mohammad Hasanain, Chittaranjan Behera, Avneet Kour, Arjun Singh, Suaib Luqman, et al. Antiproliferative Efficacy of Curcumin Mimics through Microtubule Destabilization. European Journal of Medicinal Chemistry. 2018; 151: 51–61. https://doi.org/10.1016/j.ejmech.2018.03.063.

10. Kumar, Balagani Sathish, Kusumoori Ravi, Amit Kumar Verma, Kaneez Fatima, Mohammad Hasanain, Arjun Singh, Jayanta Sarkar, Suaib Luqman, Debabrata Chanda, and Arvind S. Negi. Synthesis of Pharmacologically Important Naphthoquinones and Anticancer Activity of 2-Benzyllawsone through DNA Topoisomerase-II Inhibition. Bioorganic and Medicinal Chemistry. 2017; 25(4): 1364–73. https://doi.org/10.1016/j.bmc.2016.12.043.

11. Mishra, Disha, Jyotshna, Arjun Singh, D. Chanda, K. Shanker, and Puja Khare. Potential of Di-Aldehyde Cellulose for Sustained Release of Oxytetracycline: A Pharmacokinetic Study. International Journal of Biological Macromolecules. 2019; 136: 97–105. https://doi.org/10.1016/j.ijbiomac.2019.06.043.

12. Sathish Kumar, B., Amit Kumar, Jyotsna Singh, Mohammad Hasanain, Arjun Singh, Kaneez Fatima, Dharmendra K. Yadav, et al. Synthesis of 2-Alkoxy and 2-Benzyloxy Analogues of Estradiol as Anti-Breast Cancer Agents through Microtubule Stabilization.” European Journal of Medicinal Chemistry. 2014; 86: 740–51. https://doi.org/10.1016/j.ejmech.2014.09.033.

13. Sathish Kumar, B., Aastha Singh, Amit Kumar, Jyotsna Singh, Mohammad Hasanain, Arjun Singh, Nusrat Masood, et al. Synthesis of Neolignans as Microtubule Stabilisers. Bioorganic and Medicinal Chemistry. 2014; 22(4): 1342–54. https://doi.org/10.1016/j.bmc.2013.12.067.

14. Singh, Aastha, Kaneez Fatima, Arjun Singh, Akansha Behl, M. J. Mintoo, Mohammad Hasanain, Raghib Ashraf, et al. Anticancer Activity and Toxicity Profiles of 2-Benzylidene Indanone Lead Molecule. European Journal of Pharmaceutical Sciences. 2015; 76: 57–67. https://doi.org/10.1016/j.ejps.2015.04.020.

15. Singh, Aastha, Kaneez Fatima, Ankita Srivastava, Sadiya Khwaja, Dev Priya, Arjun Singh, Girish Mahajan, et al. Anticancer Activity of Gallic Acid Template-Based Benzylidene Indanone Derivative as Microtubule Destabilizer. Chemical Biology and Drug Design. 2016; 88(5): 625–34. https://doi.org/10.1111/cbdd.12805.

16. Singh, Arjun, B. Sathish Kumar, Sarfaraz Alam, Hina Iqbal, Mohammad Shafiq, Feroz Khan, Arvind S. Negi, Kashif Hanif, and Debabrata Chanda. Diethyl-4,4ʹ-Dihydroxy-8,3ʹ-Neolign-7,7ʹ-Dien-9,9ʹ-Dionate Exhibits Antihypertensive Activity in Rats through Increase in Intracellular CGMP Level and Blockade of Calcium Channels. European Journal of Pharmacology. 2017; 799: 84–93. https://doi.org/10.1016/j.ejphar.2017.01.044.

17. Singh, Arjun, B. Sathish Kumar, Hina Iqbal, Sarfaraz Alam, Pankaj Yadav, Amit Kumar Verma, Feroz Khan, et al. Antihypertensive Activity of Diethyl-4,4’-Dihydroxy-8,3’-Neolign-7,7’-Dien-9,9’-Dionate: A Continuation Study in L-NAME Treated Wistar Rats. European Journal of Pharmacology. 2019; 858: 172482. https://doi.org/10.1016/j.ejphar.2019.172482.

18. Singh, Arjun, Ipsita Mohanty, Jagmohan Singh, and Satish Rattan. BDNF Augments Rat Internal Anal Sphincter Smooth Muscle Tone via RhoA/ROCK Signaling and Nonadrenergic Noncholinergic Relaxation via Increased NO Release. American Journal of Physiology-Gastrointestinal and Liver Physiology. 2020; 318(1): G23–33. https://doi.org/10.1152/ajpgi.00247.2019.

19. Singh, Arjun, and Satish Rattan. BDNF Rescues Aging-Associated Internal Anal Sphincter Dysfunction. American Journal of Physiology-Gastrointestinal and Liver Physiology. 2021; 321(1): G87–97. https://doi.org/10.1152/ajpgi.00090.2021.

20. Singh, Arjun, Jagmohan Singh, and Satish Rattan. Evidence for the Presence and Release of BDNF in the Neuronal and Non‐neuronal Structures of the Internal Anal Sphincter. Neurogastroenterology and Motility. 2021. https://doi.org/10.1111/nmo.14099.

21. Srivastava, Ankita, Kaneez Fatima, Eram Fatima, Arjun Singh, Aastha Singh, Aparna Shukla, Suaib Luqman, et al. Fluorinated Benzylidene Indanone Exhibits Antiproliferative Activity through Modulation of Microtubule Dynamics and Antiangiogenic Activity. European Journal of Pharmaceutical Sciences. 2020; 154: 105513. https://doi.org/10.1016/j.ejps.2020.105513.

22. Yadav, Pankaj, Hina Iqbal, Kapil Kumar, Parmanand Kumar, Divya Mishra, Arjun Singh, Anirban Pal, et al. 2-Benzyllawsone Protects against Polymicrobial Sepsis and Vascular Hyporeactivity in Swiss Albino Mice. European Journal of Pharmacology. 2022; 917: 174757. https://doi.org/10.1016/j.ejphar.2022.174757.

23. Arjun Singh. A Review of various aspects of the Ethnopharmacological, Phytochemical, Pharmacognostical, and Clinical significance of selected Medicinal plants. Asian Journal of Pharmacy and Technology. 2022; 12(4): 349-0. doi: 10.52711/2231-5713.2022.00055

24. Singh, Aastha, Fatima, K., Srivastava, A., Khwaja, S., Priya, D., Singh, Arjun, Mahajan, G., Alam, S., Saxena, A.K., Mondhe, D.M., Luqman, S., Chanda, D., Khan, F., Negi, A.S. Anticancer activity of gallic acid template-based benzylidene indanone derivative as microtubule destabilizer. Chem Biol Drug Des. 2021; 88: 625–634.

25. Yadav, P., Iqbal, H., Kumar, K., Kumar, P., Mishra, D., Singh, A., Pal, A., Mukhopadhyay, P., Vamadevan, B., Singh, D., Negi, A.S., Chanda, D. 2-Benzyllawsone protects against polymicrobial sepsis and vascular hyporeactivity in swiss albino mice. European Journal of Pharmacology. 2022; 917: 174757.

26. Manmohan, S., Arjun, S., Khan, S. P., Eram, S., and Sachan, N. K. Green chemistry potential for past, present and future perspectives. International Research Journal of Pharmacy. 2012; 3: 31-36.

27. Singh A, Kumar BS, Alam S, Iqbal H, Shafiq M, Khan F, Negi AS, Hanif K, Chanda D. Corrigendum to "Diethyl-4,4'-dihydroxy-8,3'-neolign-7,7'-dien-9,9'-dionate exhibits AH activity in rats through increase in intracellular cGMP level and blockade of calcium channels" [Eur. J. Pharmacol. 799 (2017) 84-93]. Eur J Pharmacol. 2017; 806: 111. doi: 10.1016/j.ejphar.2017.04.033. Erratum for: Eur J Pharmacol. 2017 Mar 15;799:84-93. PMID: 28495016.

28. Singh, A., R. Sharma, K. M. Anand, S. P. Khan, and N. K. Sachan. Food-drug interaction. International Journal of Pharmaceutical and Chemical Science 1, no. 1 (2012): 264-279.

29. Thanh-Hoang, N.-V.; Loc, N.; Nguyet, D.; Thien-Ngan, N.; Khang, T.; Cao, H.; Le, L. Plant Metabolite Databases: From Herbal Medicines to Modern Drug Discovery. J. Chem. Inf. Model. 2020; 60: 1101–1110.

30. Kumar, S.; Malhotra, R.; Kumar, D. Euphorbia hirta: Its chemistry, traditional and medicinal uses, and pharmacological activities. Pharmacogn. Rev. 2010; 4: 58–61.

31. Arjun Singh. A Review of various aspects of the Ethnopharmacological, Phytochemical, Pharmacognostical, and Clinical significance of selected Medicinal plants. Asian Journal of Pharmacy and Technology. 2022; 12(4): 349-0. doi: 10.52711/2231-5713.2022.00055

32. Singh, A., Chanda, D., & Negi, A. S. Antihypertensive activity of Diethyl-4, 4'-dihydroxy-8, 3'-neolign-7, 7'-dien-9, 9'-dionate through increase in intracellular cGMP level and blockade of calcium channels (VDCC) and opening of potassium channel and in vivo models (SHRs and L-NAME induced hypertension). In Proceedings for Annual Meeting of The Japanese Pharmacological Society WCP2018 (The 18th World Congress of Basic and Clinical Pharmacology) 2018 (pp. PO1-2). Japanese Pharmacological Society.

33. Ritik S. Jain, Tejas G. Jain, Suraj K. Ishikar. Impact of Covid-19 on Changing Habits and Health Issues of the Public. Asian Journal of Management. 2020; 11(4): 524-528.

34. Vishnu P K, Anil P V, Vyshak P K. Adaptation towards Green banking; exploring acceptance and awareness among stakeholders of Banking Industry; A Post COVID-19 outbreak analysis. Asian Journal of Management. 2022; 13(3): 186-2.

35. Hariprasath Pandurangan. Middle East Respiratory Syndrome (MERS) a Threat to Asian Countries. Asian J. Nursing Education and Research. 2018; 8(3): 375-378.

36. Rashmi Negi, Arti. Novel Coronavirus (COVID 19) Knowledge and Perception: A Survey of Healthcare workers. Asian Journal of Nursing Education and Research. 2021; 11(4): 503-9.

37. Usha N S, Sushmitha H S, Vinay Kumar G. A Study to assess side effects of first dose of Covid-19 Vaccination among GNM students studying at JSS School of Nursing Chamarajanagar. Asian Journal of Nursing Education and Research. 2021; 11(4): 552-4.

38. Rashmi Negi, Khushbu Saharan, Kavita Pillai. Knowledge regarding Immunity Boosting Measures for Self-care during COVID-19 crisis: Survey of Urban Community in Haryana. Asian Journal of Nursing Education and Research. 2021; 11(4): 488-4.

39. Devender Paswan, Urmila Pande, Alka Singh, Divya Sharma, Shivani Kumar, Arjun Singh. Epidemiology, Genomic Organization, and Life Cycle of SARS CoV-2. Asian Journal of Nursing Education and Research. 2023; 13(2): 141-4.

40. Arjun Singh, Rupendra Kumar, Sachin Sharma. Natural products and Hypertension: Scope and role in Antihypertensive Therapy. Asian Journal of Nursing Education and Research. 2023; 13(2): 162-6.

41. Arjun Singh. A Review of various aspects of the Ethnopharmacological, Phytochemical, Pharmacognostical, and Clinical significance of selected Medicinal plants. Asian Journal of Pharmacy and Technology. 2022; 12(4): 349-0.

42. Arjun Singh, Rupendra Kumar. An Overview on Ethnopharmacological, Phytochemical, and Clinical Significance of Selected Dietary Polyphenols. Asian Journal of Research in Chemistry. 2023; 16(1): 8-2.

43. Arjun Singh. Plant-based Isoquinoline Alkaloids: A Chemical and Pharmacological Profile of Some Important Leads. Asian Journal of Research in Chemistry. 2023; 16(1): 43-8.

Received on 06.01.2023 Modified on 14.04.2023

Asian Journal of Management. 2023;14(4):227-232.

DOI: 10.52711/2321-5763.2023.00038